Literature DB >> 7337962

Depressed spontaneous cellular cytotoxicity associated with normal or enhanced antibody-dependent cellular cytotoxicity in patients on chronic haemodialysis.

A M Badger, D B Bernard, B A Idelson, S R Cooperband.   

Abstract

Lymphocyte function as assessed by spontaneous cellular cytotoxicity (NK) and antibody-dependent cellular cytotoxicity (ADCC) was studied in a group of 23 patients with end-stage renal disease who were being maintained on haemodialysis. The mononuclear cells from 12 (50%) of these patients were markedly reduced in their ability to effect NK activity. When mononuclear cells from 13 patients were examined for ADCC activity, however, only two displayed reduced cytotoxicity. The remainder showed either normal or enhanced ADCC activity against erythrocyte targets. Five patients with consistently low NK cell function demonstrated a significantly enhanced ADCC function when compared with normal controls. Several patients were tested repeatedly over a period of 6 months and we found that these two mononuclear cell functions remained consistent during this time. A reduction in NK activity may reflect a lessened capability for immunosurveillance in these patients.

Entities:  

Mesh:

Year:  1981        PMID: 7337962      PMCID: PMC1537399     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Prolonged survival of skin homografts in uremic patients.

Authors:  G J DAMMIN; N P COUCH; J E MURRAY
Journal:  Ann N Y Acad Sci       Date:  1957-03-22       Impact factor: 5.691

2.  Production of antbody in patients with uremia.

Authors:  I L STOLOFF; R STOUT; R M MYERSON; W P HAVENS
Journal:  N Engl J Med       Date:  1958-08-14       Impact factor: 91.245

3.  The effect of severe battle injury and of post-traumatic renal failure on resistance to infection.

Authors:  H H BALCH
Journal:  Ann Surg       Date:  1955-08       Impact factor: 12.969

4.  Differential effects of ouabain on human cell-mediated cytotoxicity. I. Inhibition of mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity against chicken red cell targets.

Authors:  E C Lawrence; A V Muchmore; N J Dooley; R M Blaese
Journal:  Cell Immunol       Date:  1979-08       Impact factor: 4.868

5.  Antibody-dependent cellular cytotoxicity effector cell capability among normal individuals.

Authors:  D L Edwards; F P Avis
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

6.  Dissociation of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity in kidney allograft recipients receiving high-dose immunosuppressive therapy.

Authors:  M Lipinski; T Tursz; H Kreis; Y Finale; J L Amiel
Journal:  Transplantation       Date:  1980-03       Impact factor: 4.939

7.  Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production.

Authors:  M Lipinski; J L Virelizier; T Tursz; C Griscelli
Journal:  Eur J Immunol       Date:  1980-04       Impact factor: 5.532

8.  Comparison of the effector cells in human spontaneous cellular cytotoxicity and antibody-dependent cellular cytotoxicity: differential sensitivity of effector cells to in vivo and in vitro corticosteroids.

Authors:  J E Parrillo; A S Fauci
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

9.  Natural killing in immunodeficient patients.

Authors:  H S Koren; D B Amos; R H Buckley
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

10.  Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function.

Authors:  M Klein; J Roder; T Haliotis; S Korec; J R Jett; R B Herberman; P Katz; A S Fauci
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

View more
  1 in total

Review 1.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.